Dr. Paula Rodriguez-Otero on a Pooled Analysis of the O-12-MI and HORIZON Studies

What is the background of this study?

Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that leverages aminopeptidases and rapidly releases alkylating agents inside tumor cells. Melflufen has a mechanism of action distinct from other alkylating agents (Slipicevic et al. AACR 2020. Abs. 1843). In the O-12-M1 (NCT01897714) and HORIZON (OP-106; NCT02963493) studies, melflufen plus dex showed meaningful efficacy and a clinically manageable safety profile in pts with RRMM (Richardson et al. Lancet Haematol. 2020;7:5; Richardson et al. J Clin Oncol. 2020;Dec 9 [Epub]). This pooled analysis examines pts from these studies exposed to prior alkylators.

In this video:

Dr. Paula Rodriguez-Otero (Clínica Universidad de Navarra, Pamplona, Spain) discusses the results of the pooled analysis of the O-12-M1 and HORIZON studies.

Conclusions:

Melflufen in combination with dex showed meaningful efficacy and a clinically manageable safety profile in pts with RRMM exposed/refractory to prior alkylators.

Clinical trial information: NCT02963493 (http://clinicaltrials.gov/show/NCT02963493%20and%20NCT01897714) and NCT01897714 (http://clinicaltrials.gov/show/NCT02963493%20and%20NCT01897714)